At the time of writing, Verona Pharma Plc ADR [VRNA] stock is trading at $34.26, up 4.85%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The VRNA shares have gain 6.90% over the last week, with a monthly amount glided 15.04%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Verona Pharma Plc ADR [NASDAQ: VRNA] stock has seen the most recent analyst activity on October 03, 2024, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $50. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $31 on August 26, 2022. H.C. Wainwright initiated its recommendation with a Buy and recommended $25 as its price target on September 13, 2021. Jefferies started tracking with a Buy rating for this stock on August 25, 2020, and assigned it a price target of $17. In a note dated August 10, 2020, Canaccord Genuity initiated an Buy rating and provided a target price of $17 on this stock.
For the past year, the stock price of Verona Pharma Plc ADR fluctuated between $11.39 and $32.96. Currently, Wall Street analysts expect the stock to reach $33 within the next 12 months. Verona Pharma Plc ADR [NASDAQ: VRNA] shares were valued at $34.26 at the most recent close of the market. An investor can expect a potential drop of -3.68% based on the average VRNA price forecast.
Analyzing the VRNA fundamentals
Gross Profit Margin for this corporation currently stands at 0.05% with Operating Profit Margin at -137.94%, Pretax Profit Margin comes in at -134.41%, and Net Profit Margin reading is -133.65%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.55 and Total Capital is -0.34. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.29.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 32.94 points at the first support level, and at 31.63 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.13, and for the 2nd resistance point, it is at 36.01.
Ratios To Look Out For
It is important to note that Verona Pharma Plc ADR [NASDAQ:VRNA] has a current ratio of 8.61. In addition, the Quick Ratio stands at 8.61 and the Cash Ratio stands at 8.37.
Transactions by insiders
Recent insider trading involved ZACCARDELLI DAVID, President and CEO, that happened on Sep 11 ’24 when 0.6 million shares were sold. Chief Financial Officer, Hahn Mark W completed a deal on Sep 11 ’24 to sell 0.6 million shares. Meanwhile, Officer MARK HAHN bought 75000.0 shares on Sep 11 ’24.
